. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Circ Cardiovasc Genet. 2013 Jul 22;6(4):400–408. doi: 10.1161/CIRCGENETICS.113.000099

Table 2.

Plasma statin concentration linear regression model coefficients from prospective cohort

	Variable	Effect (B)	p value
Atorvastatin-treated patients (n = 128)
1	Age (yr)	0.018	0.002
2	4β-hydroxycholesterol	−0.015	0.006
3	SLCO1B1 c.521T>C	0.339	0.020
4	SLCO1B1 c.388A>G	−0.278	0.009
Rosuvastatin-treated patients (n = 130)
1	Age (yr)	0.012	0.005
2	SLCO1B1 c.521T>C	0.413	<0.001
3	ABCG2 c.421C>A	0.310	0.020

Adjusted for gender, ethnicity, BMI, dose and time from last dose. Dose and time from last dose were significant in both models (p < 0.001 for atorvastatin and rosuvastatin). Coefficients for all variables for atorvastatin and rosuvastatin are described in Supplemental Tables 3 and 4, respectively.